AEZS Aeterna Zentaris Inc.

2.55
-0.15  -5.56%
Previous Close 2.70
Open 2.75
Price To book 8.31
Market Cap 29.76M
Shares 11,670,000
Volume 205,493
Short Ratio 2.98
Av. Daily Volume 325,139

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 4, 2017 - trial failed.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 data due 1Q 2017.
Zoptrex
Endometrial cancer

Latest News

  1. Biotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris
  2. Dryships, Agile Therapeutics in Thursday’s 52-Week Low Club
  3. AEterna Zentaris Inc. (USA) (AEZS) Is Down, But Probably Not Out
  4. 01.04.2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
  5. Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
  6. Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
  7. Aeterna Zentaris 3Q Loss $6M or 61c/Share (AEZS)
  8. AEterna Zentaris Inc. (USA) (AEZS) Lines Up A Binary Event Reversal For The First Quarter
  9. 11.08.2016 Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results
  10. Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results
  11. 11.01.2016 Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common Shares and Warrants
  12. Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common Shares and Warrants
  13. Here Are Three Big Biotech Movers And Our Take On What’s Next
  14. 10.28.2016 Aeterna Zentaris to Announce Third Quarter 2016 Financial and Operating Results on November 8, 2016
  15. Aeterna Zentaris to Announce Third Quarter 2016 Financial and Operating Results on November 8, 2016
  16. 10.27.2016 Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering of Common Shares and Warrants
  17. Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering of Common Shares and Warrants
  18. 10.26.2016 Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen™
  19. Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen™
  20. Aeterna Zentaris (AEZS) Jumps: Stock Adds 5.2% in Session